NKTR
Nektar Therapeutics

Nektar TherapeuticsNKTR

Healthcare · Biotechnology
37.97USD
+1.39%
Oct 28, 2026
NKTR overview ready
Advancing Immune Tolerance Restoration with Rezpegaldesleukin in Autoimmune Diseases
Nektar is a clinical-stage, largely single-asset immunology developer whose principal value driver is rezpegaldesleukin, a regulatory-T-cell-stimulating biologic being advanced toward potential treatment of atopic dermatitis, alopecia areata and type 1 diabetes.
Narrative is still early
Exposed to the Autoimmune Disease Treatment Innovation narrative through Immune Tolerance Restoration Therapeutics — pure play.
Price action is under distribution
Longer-term context reads extended trend, with a near-term setup of constructive pullback.
Demanding valuation
The price embeds expectations that run ahead of the cash it currently generates.
Fundamentals not measured
Primary risk
Clinical trial failure or delays.
Market Oct 27Filing Jun 30Price action Sep 10Research Aug 29

Conviction Level

CompanyFit6.0PriceAction6.0Valuation1.7CompanyPosition7.3BusinessQuality—

Conviction uses Company Fit, Price Action, Valuation, Business Quality. Company Position is research context, not an input.

Theme leadershipGroup context · not a Conviction input
vs SPY
−3.6pp
Theme return
−3.1%
Beating SPY
6 of 21
21 sessions to Oct 27, 2026 · ranked 30 of 59 themes
Price
Loading price history…

Price Action

Price action is under distribution
Longer-term context reads extended trend, with a near-term setup of constructive pullback.
EntryReset + recovery

The stock remains extended from its long-term weekly base, but the recent reset toward the daily SMA200 aligned with support at the weekly EMA21. Daily structure is recovering above the fast averages, improving the current entry location.

Key Financials

Market Cap
$1.3B
Avg Volume (60D)
1.4M
60 sessions
Revenue Growth YoY
-43.9%
FY2025 vs FY2024
Gross Margin
+100.0%
Operating Margin
-257.8%
Trailing twelve months
Free Cash Flow Yield
-18.1%
P/E
N/M
Market metrics as of Oct 27, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

Both valuation perspectives agree this company is expensive.
This company has an Expensive valuation stance because the price embeds expectations that run ahead of the cash it currently generates.

Company Research

Thesis
Nektar is a clinical-stage, largely single-asset immunology developer whose principal value driver is rezpegaldesleukin, a regulatory-T-cell-stimulating biologic being advanced toward potential treatment of atopic dermatitis, alopecia areata and type 1 diabetes.
Opportunity
Moderate opportunity
Development of therapies intended to restore immune tolerance or rebalance dysregulated immunity in autoimmune and chronic inflammatory diseases, rather than only suppress inflammatory pathways downstream.
Key risk
Clinical trial failure or delays.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Nektar Therapeutics discovers and develops immunotherapy medicines targeting autoimmune disorders, inflammatory diseases, fibrotic diseases, and cancers, operating through clinical development and collaborations.

How it earns

The company generates revenue primarily through licensing agreements, collaborations, and potential future product sales.

Products & services
Rezpegaldesleukin
NKTR-0165
NKTR-0166
NKTR-422
NKTR-255
Customers & end markets
Pharmaceutical companies
Healthcare providers
Patients with autoimmune and inflammatory diseases, fibrotic diseases, and cancers
Market position

Nektar operates as a niche biotechnology company focused on immunotherapy with several early to mid-stage clinical assets.

Demand drivers
Low cyclicality

Demand for biopharmaceutical innovation in immunotherapy is relatively stable and driven by medical need rather than economic cycles.